Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders
As a research compound, AOD9604 UK carries a well-characterised pre-clinical and early-phase clinical research profile developed primarily through the work of Metabolic Pharmaceuticals, with published studies spanning lipid metabolism, adipose biology, 3-adrenergic receptor regulation, cartilage biology, and safety pharmacology
Following your initial treatment period, you might need to receive the shots once a month for three months, and then reduce it to once every three months
Intramuscular and intravenous delivery bypasses the gastrointestinal tract, achieving significantly higher bioavailability than oral supplementation, making injectable micronutrients a clinically effective option for patients with confirmed or suspected deficiency, malabsorption conditions, or chronic illness
US$ 26.05
US$ 26.97
US$ 20.32
